Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Revenue	1.41	-	-	-	-
Cost of Revenue	28.54	41.76	26.45	42.33	38.96
Gross Profit	-27.12	-41.76	-26.45	-42.33	-38.96
Selling, General & Admin	39.94	29.94	26.67	20.74	12.77
Operating Expenses	39.94	29.94	26.67	20.74	12.77
Operating Income	-67.06	-71.7	-53.13	-63.07	-51.73
Interest Expense	-0.28	-3.16	-2.53	-1.49	-0.94
Interest & Investment Income	0.09	0.91	0.97	-	-
Earnings From Equity Investments	-0.14	-0.1	-0.01	-0.05	-0.05
Other Non Operating Income (Expenses)	9.49	1.15	0.05	0.47	-0.45
EBT Excluding Unusual Items	-57.9	-72.91	-54.65	-64.14	-53.16
Other Unusual Items	-6.07	-2.46	-4.33	-1.91	-
Pretax Income	-63.98	-75.36	-58.98	-66.05	-53.16
Income Tax Expense	-1.55	0	0	0	0
Earnings From Continuing Operations	-62.42	-75.37	-58.98	-66.05	-53.16
Net Income	-62.42	-75.37	-58.98	-66.05	-53.16
Net Income to Common	-62.42	-75.37	-58.98	-66.05	-53.16
Shares Outstanding (Basic)	35	19	13	11	8
Shares Outstanding (Diluted)	35	19	13	11	8
Shares Change (YoY)	87.59%	48.29%	17.96%	38.91%	110.43%
EPS (Basic)	-1.79	-4.06	-4.72	-6.23	-6.96
EPS (Diluted)	-1.79	-4.06	-4.72	-6.23	-6.96
Free Cash Flow	-51.83	-68.79	-42.97	-56.67	-54.25
Free Cash Flow Per Share	-1.49	-3.71	-3.44	-5.34	-7.11
Operating Margin	-4744.25%	-	-	-	-
Profit Margin	-4416.22%	-	-	-	-
Free Cash Flow Margin	-3666.65%	-	-	-	-
EBITDA	-66.94	-71.59	-53.08	-62.87	-51.46
D&A For EBITDA	0.12	0.11	0.04	0.2	0.26
EBIT	-67.06	-71.7	-53.13	-63.07	-51.73

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q